At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 17, 2026 at 16:05 ET
Trevi Therapeutics reported fourth quarter and full-year 2025 financial results, highlighted by a reduced net loss and $188.3 million in cash, providing runway into 2028. The company gained FDA alignment on its Phase 3 program for IPF-related chronic cough and plans to initiate pivotal trials in 2026, alongside Phase 2b trials in RCC and non-IPF ILD. Despite no revenue, R&D spending declined while cash position strengthened.
- Ended 2025 with $188.3 million in cash, cash equivalents, and marketable securities, up from $107.6 million in 2024.
- Net loss for Q4 2025 was $8.3 million vs. $11.4 million in Q4 2024; full-year net loss was $42.8 million vs. $47.9 million in 2024.
- R&D expenses decreased to $33.5 million in 2025 from $39.4 million in 2024 due to reduced clinical trial activity.
- Gained FDA alignment on Phase 3 trial design for IPF-related chronic cough; first pivotal trial to start in Q2 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access